Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Nivolumab (BMS-936558)

15 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    VICCHN1794

    03/15/2018

    Window-of-Opportunity Trial of Nivolumab and Tadalafil in Patients with Squamous Cell Carcinoma of the Head and Neck

    Treatment

    VICCUROP1777

    04/06/2018

    A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

    Treatment

    VICCBRE1674

    03/01/2018

    Phase I/II Study of Cisplatin plus Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation-Associated Locally Recurrent or Metastatic Breast Cancer

    Treatment

    VICCTHO16117

    12/29/2017

    An Open Label, Phase 2 Trial of Nivolumab in Non-small Cell Lung Cancer with High Mutation Loads

    Treatment

    VICCPHI1737

    12/01/2017

    A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors

    Treatment

    ECOGMDS1609

    10/19/2017

    DART: Dual Anti-Ctla-4 and Anti-Pd-1 Blockade in Rare Tumors

    Treatment

    VICCTHO1729

    09/14/2017

    A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination with Nivolumab or Nivolumab and Ipilimumab for Adults with Extensive- Stage Small Cell Lung Cancer

    Treatment

    VICCTHO1718

    08/17/2017

    Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

    Treatment

    VICCTHO16139

    06/13/2017

    A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

    Treatment

    ECOGUROEA8143

    06/09/2017

    PHIII Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy.

    Treatment

    VICCNEU1688

    04/28/2017

    A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (Tumor O6-methylguanine DNA methyltransferase) Glioblastoma

    Treatment

    VICCNEU1644

    04/28/2017

    A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma

    Treatment

    VICCGI1655

    12/14/2016

    A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

    Treatment

    VICCHEMP1615

    07/21/2016

    A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects with Advanced Malignancies

    Treatment

    ECOGTHOS1400

    04/02/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer


    Print this page for your doctor